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243 Assessment of the inﬂuence of air ﬂow on the volume of
NaCl 0.9% remaining in eFlow® aerosol chamber after completion
of inhalation
Z. Podolec1, J. Siekaniec1. 1Dept. of Aerosology and Aerosol Bioengineering,
Research and Development Centre MEDiNET, Cracow, Poland
Introduction: eFlow® rapid nebulizer is widely used in clinical trials and medical
practice in treatment of cystic ﬁbrosis. Reason for research was the patients’
observation that after ﬁnishing of inhalation the certain volume of drug remains in
nebulizer’s aerosol chamber. The aim of the research was to assess the inﬂuence of
the constant air ﬂow on the volume of NaCl 0.9% remaining in aerosol chamber
after automatic termination of inhalation.
Method: eFlow® nebulizer was connected with the source of constant air ﬂow:
30, 60, 90 L/min until the automatic end of inhalation of 5ml NaCl 0.9%. The
volume of NaCl 0.9% in aerosol chamber was measured by weight method. That
method consists in comparison of the weight of the aerosol chamber before and
after the end of inhalation.
Results: The statistically signiﬁcant inﬂuence of constant air ﬂow on amount of
drug in aerosol chamber which equaled to 0.526, 1.165 and 1.342 g for air ﬂow
30, 60 and 90 L/min respectively was stated. Our study demonstrate that constant
air ﬂow through eFlow® causes a loss of drug in aerosol chamber the size of which
depends on the volume of air ﬂow. eFlow® is ventilated nebulizer. The probable
reason of drug retention in aerosol chamber is vacuum pressure which depends on
the inspiratory valve resistance and volume of air ﬂow. That vacuum pressure can
cause partial loss of ability to produce drug by nebulizer. Inﬂuence of ﬂow on the
quality of aerosol during aerosol inhalation was stated in varying degrees in all
ventilated nebulizers.
Conclusion: Aerosol inhalation using ventilated nebulizers requires detailed expla-
nation of the optimal method of inhalation to the patient.
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the quality of the aerosol of rhDNase, budesonid, salbutamol and
NaCl 0.9%
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Introduction: The aim of the study was to assess the inﬂuence of the constant air
ﬂow through the aerosol’s chamber on the aerosol’s dose and particle size.
Method: Aerosol’s dose and particle size was measured by laser diffraction method
for 1 min using constant air ﬂow through aerosol chamber equal to 30, 60 and
90 l/min respectively. The effect of air ﬂow on the distribution of aerosol particles
of rhDNAse, budesonid, salbutamol and NaCl 0.9% has been evaluated. The dose
value and MMAD have been calculated from 10 measurements.
Results: Statistically signiﬁcant and proportional to increase of air ﬂow, decrease in
dose and particle size was stated for all drugs. MMAD values dependent on air ﬂow
(30, 60, 90 l/min) equaled to: for rhDNase: 2.91, 1.21 and 0.51 mm; for Salbutamol:
2.89, 0.80, 0.51mm; for NaCl 0.9%: 2.93, 0.83 and 0.50mm respectively. For
Budesonid MMAD values equaled to 2.97, 1.05mm for air ﬂow 30 and 60 l/min,
whereas for air ﬂow 90 l/min the presence of particles was not recorded by particle
counter. Our study demonstrates that constant air ﬂow through electronic eFlow®
nebulizer has a signiﬁcant inﬂuence on the aerosol’s particle size and on mass of
inhaled drug. Adjustment of the size of aerosol’s particles to the ﬂow of inhaled
air could be really interesting to obtain an increase of aerosol’s deposition in the
respiratory tract if the dose would not decrease.
Conclusion: It is recommended to make changes in the design of the nebulizer
and to broaden the scope of research in order to use in practice possibilities of
adaptation of quality of aerosol to the patients’ breathing pattern.
245 Hyaluronic acid improves tolerability of hypertonic saline in
CF patients
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Question: Inhaled hypertonic saline (HS) improves lung function and decreases
pulmonary exacerbations in people with cystic ﬁbrosis (CF). However, side effects
such as cough and airway narrowing cause intolerance of the therapy in 8% of
patients. We aimed to test the effect of the addition of 0.1% hyaluronic acid to HS
on side effects.
Aim of the study: Evaluate safety and tolerability of 0.1% HA added to HS
administered to patients with CF older than 6 years.
Methods: 30 CF patients (age 13.3±0.5, FEV1 86.7±0.4, BMI 19.4±0.4) treated
twice-daily with inhalation of 7% HS were randomized to inhale 7% HS or
HS solution added to 0.1% HA on the following day, in a single blind cross-over
design. All participants rated following symptoms: cough, throat irritation, saltiness
with a 4-point ordinal score from absent to severe. Also rated pleasantness of the
treatments using a 5-level, Likert-type scale from very unpleasant to very pleasant.
Results: Signiﬁcative difference of scores were found in patients treated with HS
and HA vs HS alone (p< 0.05). Cough: HS induced cough in 27/30 patients (90%).
HS with HA induced cough in 13/30 patients (43%). Throat irritation in 22/30
(73%) after HS. Throat irritation in 4/30 (13.3%) after HS with HA. Salty taste:
All patients treated with HS referred salty taste, only 3/30 (10%) with HS+HA.
Patients showed pleasantness signiﬁcantly higher when treated with HS added to
HA (3.0±0.2 vs 4.45±0.1).
Conclusion: HA added to HS is generally safe and well tolerated. This novel
approach could be a new tool for improving compliance to treatment with HS in
collaborative patients with CF. Clinical trials are needed to support our results.
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Objectives: Poor adherence to nebulised treatment is a well-recognised problem
in the management of pulmonary disease in children with CF. Adaptive aerosol
delivery (AAD) devices reduce treatment times and may aid adherence. Nebulisation
time can be reduced further in the I-neb™ AAD device by improving inhalation
technique using a TIM (target inhalation mode) mouthpiece. This controls maximum
inspiratory ﬂow, setting targets to be achieved on each inhalation via a vibration,
encouraging longer, slower breaths, thereby reducing total nebulisation time. The
effect of introducing this device on adherence in children was investigated.
Methods: I-neb™ usage data for children with CF attending the Birmingham
Children’s Hospital, UK was collected. Data was downloaded from the device for
the 3 months prior to the new TIM mouthpiece being demonstrated and ﬁtted and
for the subsequent 3 months.
Results: Prior to the change of mouthpiece, average duration of treatment in the
20 children (9M:11F) (median age 12.3 yrs: range 8.3–17.3 yrs) was 8.9 minutes.
Median adherence was 88% of total treatments prescribed (range 4–102%). After the
TIM mouthpiece was introduced, average treatment time was signiﬁcantly reduced
to 4.45 minutes (P< 0.001). Median adherence was 88.5% (range 57–100%). There
was a more marked improvement in those with adherence <90% at the start although
this did not reach statistical signiﬁcance.
Conclusions: A change in the pattern of inhalation using an AAD signiﬁcantly
reduces nebulisation times. This impacts positively on the burden of treatment and
may also improve adherence particularly in those patients who are less adherent to
their treatment.
